Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure
- 1 October 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (10) , 4522-4524
- https://doi.org/10.1128/aac.00651-09
Abstract
We characterized the raltegravir (RAL) susceptibility and the integrase (IN)-mediated replication capacity (RC) of RAL-resistant human immunodeficiency virus type 1 from two patients experiencing virologic failure during continuous RAL salvage therapy. The following two distinct outcomes were observed: (i) the selective outgrowth of virus with high-level RAL resistance and high IN-mediated RC leading to significant viral load rebound and (ii) the selection of virus with a slight reduction in RAL susceptibility and low IN-mediated RC resulting in sustained low-level viremia.Keywords
This publication has 6 references indexed in Scilit:
- Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance In VivoJournal of Virology, 2012
- Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patientsJournal of Antimicrobial Chemotherapy, 2009
- Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy*HIV Medicine, 2008
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008
- Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4Antiviral Therapy, 2008
- A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2000